/
Other
ESS
54
Pipeline Programs↗
47
Active Trials↗
121
Companies Involved↗
ESS is a moderately active landscape with 54 programs across 121 companies. The most active players are Argenx, Bayer, Novartis. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical27
Phase 111
Phase 215
Approved
No programs
Analysis
Modality Breakdown
88%
Small molecule
43 of 49 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 49 classified programs, each share of the total. Modality classified for 100% of 54 pipeline programs.
Analysis
Trial Status
752
clinical trials
Completed455 · 61%
Unknown status68 · 9%
No longer available61 · 8%
Terminated45 · 6%
Available36 · 5%
Recruiting27 · 4%
Other60 · 8%
Clinical Trials
Trial Activity
752 trials
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
Recruiting·—·N/A·NCT06338865·294 enrolled
Assessment of Synaptic Density in MS
Recruiting·—·Phase 1·NCT04634994·30 enrolled
Ensuring Access to Optimal Therapy in CF: The ENACT Study
Recruiting·—·Phase 4·NCT07148739·95 enrolled
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Recruiting·—·Phase 1·NCT02356653·100 enrolled
Page 1 of 51
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)